Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
136
NCT01141491
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Phase: Phase 2
Role: Lead Sponsor
Start: Jun 30, 2010
Completion: Mar 10, 2017